Kymera Therapeutics, Inc.

NasdaqGM:KYMR Stock Report

Market Cap: US$2.6b

Kymera Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:KYMR Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
06 Jan 25SellUS$130,645Ellen ChiniaraIndividual3,129US$41.75
20 Aug 24BuyUS$46Baker Bros. Advisors LPCompany1US$46.41
09 Jul 24SellUS$3,010,224Atlas Venture L.P.Company78,776US$39.26
12 Jun 24SellUS$102,973Atlas Venture L.P.Company2,905US$36.02
23 May 24SellUS$90,105Jeremy ChadwickIndividual2,575US$34.99
15 Mar 24SellUS$400,462Atlas Venture L.P.Company10,008US$41.51
13 Mar 24SellUS$439,939Atlas Venture L.P.Company10,268US$43.42
04 Mar 24SellUS$164,664Bruce JacobsIndividual3,934US$43.26
04 Mar 24SellUS$139,967Jared GollobIndividual3,344US$43.26

Insider Trading Volume

Insider Buying: KYMR insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of KYMR?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders861,8381.22%
VC/PE Firms4,896,4626.95%
Hedge Funds15,657,73022.2%
Institutions49,042,56069.6%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 94.12% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
10.3%
T. Rowe Price Group, Inc.
6,645,474US$261.8m3.99%0.02%
9.26%
Baker Bros. Advisors LP
5,995,929US$236.2m0%2.32%
7.97%
BVF Partners L.P.
5,161,801US$203.4m0%7.2%
7.89%
FMR LLC
5,109,109US$201.3m5.85%0.01%
7.56%
Atlas Venture L.P.
4,896,462US$192.9m-8.48%29.85%
7.34%
The Vanguard Group, Inc.
4,753,766US$187.3m-1.42%no data
7.13%
Wellington Management Group LLP
4,618,359US$182.0m7.17%0.03%
6.95%
Avoro Capital Advisors LLC
4,500,000US$177.3m15.7%2.59%
6.5%
BlackRock, Inc.
4,211,649US$165.9m1.35%no data
4.59%
Artal Group S.A.
2,969,733US$117.0m-1.19%3.69%
2.67%
State Street Global Advisors, Inc.
1,728,144US$68.1m-9.55%no data
2.15%
Redmile Group, LLC
1,393,256US$54.9m-11.8%3.44%
2.05%
Driehaus Capital Management LLC
1,328,703US$52.4m495%0.35%
1.63%
Geode Capital Management, LLC
1,053,224US$41.5m-0.09%no data
1.62%
Rock Springs Capital Management LP
1,049,386US$41.3m-9.84%1.41%
1.11%
Jennison Associates LLC
716,933US$28.2m-10.1%0.02%
1.02%
Nello Mainolfi
659,959US$26.0m1.54%no data
1%
UBS Asset Management AG
646,148US$25.5m0.35%no data
0.93%
Deep Track Capital, LP
600,326US$23.7m-60%0.76%
0.81%
Woodline Partners LP
525,094US$20.7m1.41%0.19%
0.78%
Eventide Asset Management, LLC
507,902US$20.0m9.91%0.35%
0.77%
Avidity Partners Management, L.P.
500,000US$19.7m0%1.15%
0.73%
Dimensional Fund Advisors LP
472,626US$18.6m17.5%no data
0.71%
Morgan Stanley, Investment Banking and Brokerage Investments
462,361US$18.2m-23.8%no data
0.7%
Massachusetts Financial Services Company
453,377US$17.9m11.7%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/30 00:20
End of Day Share Price 2025/01/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Kymera Therapeutics, Inc. is covered by 27 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Zhiqiang ShuBerenberg
Etzer DaroutBMO Capital Markets Equity Research
Tazeen AhmadBofA Global Research